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ABSTRACT
The purpose of this study was to determine the specific features of
the morphological restructuring of the myocardium in the early stage of
experimental diabetes mellitus (DM). Experimental type 1 DM rat model
was developed by intraperitoneal injection of alloxan solution at a dose of
30 mg per 100 g body mass. After 1 month, 3 mL of blood was drawn by
heart puncture and the plasma separated by centrifugation for biochemi-
cal analysis. Plasma glucose, insulin, and glycosylated haemoglobin in
whole blood were determined. Light microscopy and morphometric stud-
ies were conducted of histological slices of the hearts of experimental ani-
mals. The investigation of heart morphology showed a statistically
significant alteration in chamber wall thickness in the right auricle in
rats with alloxan-induced DM. A change in cardiomyocyte diameter in
myocardium slices was observed in all chambers of DM rats except for
the left ventricle. Average cardiomyocyte diameter in rats with experi-
mental DM increased by 26.6% and 15.5% in the right auricle and right
ventricle, respectively, while average cardiomyocyte diameter in the left
auricle decreased by 20.8%. Histological investigation of the heart follow-
ing alloxan injection demonstrated, under the epicardium, distended ves-
sels of the venous collecting microcirculatory system. Aggregation and
agglutination of red blood cells and endothelial cell destruction were
found in some vessels. In the early stage of DM development, structural
alterations in the microcirculatory channels and myocardiocytes can be
observed in the heart. These structural alterations were most evident in
the right chambers of the heart. Anat Rec, 298:396–407, 2015. VC 2014
Wiley Periodicals, Inc.
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INTRODUCTION
While type 2 diabetes mellitus (DM) is the most wide-
spread form of the disease, type 1 DM, found in only
5%–10% of all diabetic cases, is no less significant, both
scientifically and clinically, particularly due to the high
prevalence of the development of complications in the
course of disease progression (Balabolkin et al., 1999;
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Boudina and Abel, 2007; Hovind et al., 2003; Nathan
et al., 2005; Poornima et al., 2006). Type 1 DM is associ-
ated with long-term complications that affect the eyes,
kidneys, and peripheral and autonomic nervous systems
(Andersen et al., 1983; Hovind et al., 2003; Nathan,
1993).
Cardiovascular disease and complications are also
more prevalent among patients with type 1 or type 2
diabetes compared to patients without diabetes (Krolew-
ski et al., 1987; Laing et al., 2003; Nrgaard et al., 1990;
Unger and Foster, 1988; Wilson et al., 1998). For
instance, type 1 diabetes is associated with at least a 10-
fold increase in cardiovascular disease as compared with
an age-matched nondiabetic population (Dorman et al.,
1984; Laing et al., 2003). Consequently, a considerable
number of both experimental (Fein et al., 1980; Joffe
et al., 1999; Hoit et al., 1999) and clinical (Drews et al.,
2004; Friedman et al., 1982; Regan et al., 1977; Rubler
et al., 1972) studies have been devoted to the investiga-
tion of cardiovascular complications associated with
diabetes.
A strong association between hyperglycemia and car-
diovascular disease has been suggested by some (Lehto
et al., 1999) but not all (Lloyd et al., 1996; Orchard
et al., 2003) researchers. The pattern of development
and pathogenesis of these disturbances, however, remain
insufficiently studied (Yu et al., 2007). Currently, it is
believed that in the pathogenesis of chronic diabetic
complications, including cardiovascular complications,
the activation of peroxidation processes and a decrease
in NADH oxidase activity play critical roles (Baynes and
Thorpe 1999; Fiordaliso et al., 2004; Ghosh et al., 2004a,
2004b; Rajagopalan et al., 1996). These alterations lead
to, in particular, the development of diabetic cardiomy-
opathy, whereby cardiomyocyte apoptosis is combined
with myocardial hypertrophy and increased collagen
deposition (Fiordaliso et al., 2001, 2004; Li et al., 2011).
Cardiomyocyte hypertrophy and successive myocardial
apoptosis and fibrosis are structural features of diabetic
cardiomyopathy that lead to not only anatomic recon-
struction of the heart primarily via alteration of heart
chamber dimensions but also functional disturbances in
myocardial contractility in the form of systolic and/or
diastolic dysfunctions (Feng et al., 2008).
It is of interest that several studies have reported
that in type 1 DM, restructuring occurs only in the left
heart chambers due to an increase in the wall thickness
of the left ventricle (LV), caused by microcirculation dis-
turbances (Hoit et al., 1999; Karamitsos et al., 2007; Yu
et al., 2007). In contrast, several studies have reported
that restructuring of the myocardium also takes place
on the right side of the heart in type 1 DM (Karamitsos
et al., 2007; Kosmala et al., 2007). It is important to
note that disturbances of the right heart chambers in
patients with DM, in the presence of cardiac insuffi-
ciency, pulmonary hypertension or previous myocardial
infarction, greatly affect quality of life, and survival
prognosis (Karamitsos et al., 2007; Marcu et al., 2006).
Currently, research investigating specific features of
the histomorphological restructuring of the myocardium,
specifically of the right cardiac chambers, in type 1 DM,
remain few (Drews et al., 2004; Kosmala et al., 2007;
Wang et al., 2007; Ze-Zhou and Jing, 2008), prompting
the present investigation. Few reports have assessed
right ventricular (RV) dysfunction or structural abnor-
mality in diabetic cardiomyopathy. For instance, a report
in a streptozotocin (STZ)-induced diabetic rat model
combined with hypertension caused by renal clipping
showed that histopathological findings of myocardial
damage were present in both ventricles, but more pre-
dominant in the RV wall than in the LV wall (Fein
et al., 1989). In terms of the responsible mechanism, the
authors speculated lung congestion due to LV failure,
which most likely caused RV overload and myocardial
damage (Fein et al., 1989). In contrast, in a diabetic
model without hypertension, LV ejection fraction (LVEF)
was significantly decreased, although LV failure was not
severe, indicating that RV remodeling is unlikely to be
brought on by backward failure through LV failure
(Nemoto et al., 2006),
The majority of studies describe the development of
diabetic cardiomyopathy in the later stages of diabetes,
generally between the 8th and 12th week after induction
of diabetes (Akula et al., 2003). In addition, many stud-
ies have aimed to reveal changes in the left chambers of
the heart. In contrast, the aim of the present study was
to determine the specific features of morphological
restructuring of the right chambers of the heart in the
early stage of experimental DM.
MATERIALS AND METHODS
Experimental Model of Type 1 DM
The experimental type 1 DM rat model was modeled
by intraperitoneal (i.p) injection of alloxan solution at a
dose of 300 mg/kg body mass, in accordance with a modi-
fied version of a standard diabetes animal model in out-
bred male rats (Danilova and Gette, 2009; Loreto and
Elina, 2009).
Alloxan produces reactive oxygen species (ROS) with
the DNA of the pancreatic islets being one of the targets
of ROS (Loreto and Elina, 2009; Malaisse, 1982). In
addition, alloxan has a high affinity to SH-containing
cellular compounds and, as a result, reduces glutathione
content. Furthermore, alloxan inhibits glucokinase, a
SH-containing protein essential for insulin secretion
induced by glucose (Szkudelski, 2001). Alloxan also has
a lower direct cytotoxic effect compared with STZ and
alloxan models of diabetes enable more accurate timing
of selected metabolic events and their pathophysiologic
consequences (Like and Rossini, 1976).
Animal Preparation and Anesthesia
The animals used in the study were quarantined in
the vivarium of the Institute of Immunology and Physi-
ology of the Ural Division of RAS (Ekaterinburg, Rus-
sia). The animals showed no symptoms of any disease.
All animals were kept under equal conditions (12 hr
light/12 hr dark), and were fed according to the custom-
ary schedule with free access to water.
All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at the
Institute of Immunology and Physiology of the Ural
Division of RAS (Ekaterinburg, Russia) and performed
in accordance with the principles formulated at the
European Convention for the Protection of Vertebrate
Animals used for Experimental and Other Scientific Pur-
poses (Strasbourg, France, 18 March 1986), APS’s Guid-
ing Principles in the Care and Use of Vertebrate
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Animals in Research and Training and in accordance
with the Laboratory Practice Regulations of RF (Insti-
tute of Laboratory Animal Research, 1996; Ministry of
Public Health Order no. 267 from 19 June 2003; Fleck-
nell, 1987; Swindle and Adams, 1988).
Animal Protocol
The experiments were carried out on 20 outbred male
rats. The animals were of the same age, received from
the rat farm at the same time, and formed the test and
the control groups. The animals were 16 weeks old.
The test group (A), consisted of 10 rats with an aver-
age body weight of 210 g. These rats received an i.p
injection of alloxan, at a dose of 300 mg/kg. For the con-
trol of disease progression, plasma glucose was deter-
mined at days 3, 7, 17, and 30. The blood was collected
from the tail vein.
The control group, Group B consisted of 10 rats with
an average bodyweight of 220 g. These rats received
saline injections. After 1 month, the animals from group
B were taken out of the experiment and euthanized with
an i.p injection of 40 mg/kg pentobarbital sodium. A
3 mL blood sample for biochemical analysis was obtained
by heart puncture, and the plasma separated by
centrifugation.
Light microscopy and morphometric studies were con-
ducted of histological slices of the hearts of experimental
animals.
Laboratory Blood Tests
Plasma glucose levels were determined by a glucose
oxidase method (Novogluk-R, «VektorBrest», Russia)
and blood glucose levels were measured using the uni-
fied glucose oxidase test. The test is based on specificity
of action of glucose oxidase enzyme. This enzyme oxi-
dizes glucose in the presence of molecular oxygen to
form gluconolactone, spontaneously hydrolyzing to glu-
conic acid. Thereafter, an equimolar quantity of hydro-
gen peroxide (22) is formed, which is degraded by the
peroxidase enzyme. As a result of the peroxidase reac-
tion, atomic oxygen oxidizes phenolphthalin. The latter
turns red, indicating the amount of glucose present
within a sample. The optical density of each sample was
measured and compared to the optical density of a sam-
ple containing a known concentration of glucose for
quantitative determination of glucose as previously
described (Butolin and Ivanov, 1998; Karpischev, 2002).
Plasma insulin was determined by an enzyme-linked
immunosorbent assay (Insulin ELISA, Mercodia AB,
Switzerland) and insulin determination performed
according to the manufacturer’s instructions (Mercodia,
Uppsala, Sweden). The Insulin ELISA test is based on
the method of a solid-phase one-step immunoenzymatic
“sandwich”-type assay. The two types of monoclonal anti-
bodies used in the test are oriented in their action at dif-
ferent antigenic determinants of the insulin molecule.
During a 2 hr incubation, the insulin present in the
sample reacts with insulin antibodies conjugated with
horseradish peroxidase and simultaneously with insulin
antibodies tied in microtiter wells during a 30 min incu-
bation period. Washing ultimately eliminates untied
enzyme-labeled antibodies. Determination of the tied
conjugate is implemented by its reaction (30 min) with
the enzyme substrate 3.3’5.5’-tetramethylbenzidine.The
reaction is stopped with the addition of acid to achieve
the colorimetric endpoint for measuring the optical den-
sity, providing the concentration of insulin as previously
described (Egorov et al., 1991; Tijssen, 1988; Yakovleva,
2005).
Glycosylated haemoglobin in whole blood was deter-
mined by thin layer chromatography («Diabetes-test»,
FOSFOSORB, Russia). Determination of glycosylated
haemoglobin was conducted by the method of affinity
chromatography. Briefly, determination of haemoglobin
was achieved using «Diabetes-test» (HbA1c)” (TOR 9398-
240-16404416-01) and was implemented in compliance
with the manufacturer’s instructions (“Fosfosorb” OJSC,
Russia) (Jeppsson et al., 2002; Yakovleva, 2005).
Biochemical testing was performed with a DU-800 spec-
trophotometer (Beckman Coulter Int S.A., Switzerland).
Preparation of Samples for Histological
and Morphological Studies
Under general ether anesthesia, the thorax cavity was
opened by midline thoracotomy. The hearts of rats were
arrested in the diastole phase with 2% lidocaine, excised
and perfuse-fixed on a Langendorff apparatus under
constant pressure with 4% paraformaldehyde in
phosphate-buffered saline (PBS). The perfusion pressure
was 100 mmHg (Koenig et al., 1945).
The hearts were stored in 4% PBS for 24 hr at 14C
temperature (RT). The standard dehydration procedure
was performed (Farmilo and Stead, 2009). The hearts
were then longitudinally cut in half through the sagit-
tal plane to determine the left and right chambers of
the atrium and the left and right chambers of the
ventricle.
The heart tissue was processed and embedded in par-
affin wax using the autoprocessor Leica EG 1160 (Leica
Mikrosysteme Vertrieb GmbH, Wetzlar, Germany)
according to the manufacturer’s instructions. Serial 3–5
micron (lm) thick sections were stained with hematoxy-
lin and eosin (H&E) to investigate cellular and myocar-
cial structural changes (Bancroft and Stevens, 1996;
Lillie, 1977; Figs. 1–5).
In addition, the hematoxylin-basic fuchsin picric acid
(HBFP or Van Gieson’s) staining method was used for
detection of myocardial lesions and defects of vessel
basement membrane, as previously described (Serov
et al., 1976; Prent, 1993; Fig. 6).
For improved visualization of structural changes in
the myocardium (i.e., degree of cardiomyocyte and con-
nective tissue stroma destruction), the triphenyl tetrazo-
lium chloride (TTC) staining method employed by Lie
et al., was conducted (Figs. 7–10; Lie et al., 1975). This
enzymatic staining technique takes advantage of inabil-
ity of ischemic myocardium (i.e., dehydrogenase-deficient
cells) to reduce TTC, resulting in a dark purplish-brown
precipitate in ischemic cells.
Heart chamber wall thickness was determined as the
length of the perpendicular to the longitudinal axis of
the wall (an average of 10 measurements was taken).
The determination of the average diameter of the car-
diomyoctes in each section of the heart was carried out
on transverse sections of 20 fields at a view of 1003
magnification regridding by 1 mm2 with the help of the
software «Morphology» 5.0 (Video Test, Russia).
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Photomicrographs were obtained with the 53 objec-
tive for measuring the wall thickness of the heart
chambers and 1003 for measuring the diameter of cardi-
omyocytes with the help of the software «Morphology»
5.0 (Video Test, Russia).
Statistical Analysis
Results are expressed as mean6 standard deviation
(SD). Data were analyzed using the nonparametric
Mann-Whitney test.
RESULTS
The biochemical analysis, 1 month after alloxan injec-
tion, revealed that the rats had successfully developed
experimental DM. The plasma glucose level in the test
animals was 27.863.5 mmol/L and 6.060.2 mmol/L in
the control group (Table 1). Plasma insulin concentra-
tions were 0.456 0.09 mg/L, 62.8% lower than control
values of 1.216 0.2 mg/L (P< 0.05), while the glycosyla-
ted haemoglobin level increased to 9.66 0.3%, 88.2%
higher than the value of 5.16 0.2% measured in the con-
trol group (P< 0.05).
The heart morphology investigation revealed a signifi-
cant alteration of chamber thickness (Table 2) only in
the right auricle in rats with alloxan-induced diabetes
with an increase of 76.2% compared with the control
group (P< 0.05).
A change in cardiomyocyte diameter in myocardium sli-
ces was observed in all heart segments except for the left
ventricle (Table 3). The average cardiomyocyte diameter
in rats with diabetes significantly increased by 26.6%
(P<0.05) and 15.5% (P< 0.05) in the right auricle and
right ventricle, respectively, while average cardiomyocyte
diameter decreased by 20.8% (P< 0.05) in the left auricle.
The results of histological investigation of the heart of
intact animals (group B) are presented in Figs. 1–6.
Histological investigation of the heart after alloxan
injection demonstrated distended vessels of the venous
collecting microcirculatory system under the epicardium
(Figs. 1, 2).
These investigations also revealed marginal adhesion
of red blood cells (RBCs) on the endothelium with (Fig.
2B) and without (Fig. 2D) aggregation. Focal destruction
of the basal membrane was observed in some vessels
(Fig. 3). In addition to structural disturbances of the
microcirculation, projection of the mesothelium and
destruction of epicardial cells was observed.
In perifocal zones, there were cardiomyocytes with
signs of myomalacia in the form of disappearance of
banding and focal sarcoplasm disintegration (Fig. 2).
Nucleus-free cardiomyocytes were also observed.
This initial stage of the development of diabetic angi-
opathy is not generally associated with the replacement
of degenerated perivascular cardiomyocytes by connec-
tive tissue. With the use of TTC staining in the current
study, however, interstitial edema and signs of ischemia
were observed in test animals while intact animals
showed no histological changes (Figs. 4, 5).
In the myocardium of right chambers of the heart, the
interstitial edema and the focal destruction of cardiomy-
ocytes formed karyolysis and karyopyknosis of nuclei
with signs of plasmorrhexis observed (Fig. 6).
TABLE 1. The plasma glucose levels in the course of experimental DM
Days of the experiment
Group 3 day 7 day 14 day 30 day
Control 5.96 0.25 5.856 0.25 6.16 0.1 6.06 0.2
Alloxan diabetes 20.46 3.7* 26.56 5.3* 27.06 4.2* 27.86 3.5*
Note: Statistically significant difference in values in case of paired comparison: *P<0.05 in comparison with control
animals.
TABLE 2. Wall thickness of heart chambers in the animal groups (lm)
Auricles Ventricles
Group Right Left Right Left
Control 443.396 52.35 1007.016 283.24 1138.24658.70 5002.946 121.82
Alloxan diabetes 781.416 259.21* 1067.646 162.2 1218.476150.00 4408.216 676.23
Note: Statistically significant difference in values in case of paired comparison: *P<0.05 in comparison with control
animals.
TABLE 3. Cardiomyocyte diameter in different heart chambers in the animal groups (lm)
Auricles Ventricles
Group Right Left Right Left
Control 10.2586 0.27 13.6316 0.72 12.59060.24 13.3566 0.37
Alloxan diabetes 12.9836 0.35* 10.7986 0.4* 14.53960.25* 12.8656 0.3
Note: Statistically significant difference in values in case of paired comparison: *P<0.05 in comparison with control
animals.
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Thus, it is clear that at early stages of diabetes, dia-
betic cardiomyopathy occurs primarily in the right
chambers of the heart. This manifests itself in the dis-
turbance of endomysium microcirculation (aggregation
and agglutination of RBCs), the consequence of which is
the development of interstitial edema, tissue hypoxia,
and the focal destruction of cardiomyocytes (Figs. 1, 2).
DISCUSSION
It is currently widely accepted that pancreatic islet b-
cell death occurs in both type 1 and type 2 DM, result-
ing in absolute or relative insulin deficiency (Donath
and Halban, 2004). Consequently, STZ- or alloxan-
induced diabetic animal models are considered excellent
animal model of type 1 DM. Nevertheless, there are
extensive limitations of these diabetic animal models
(Donath and Halban, 2004). While a single injection of
alloxan or STZ does not usually lead to an autoimmune
reaction as observed in type 1 diabetes, these diabetic
animal models still lack a significant resistance to
increased insulin action as seen in type 2 diabetes (Dyn-
tar et al., 2006).
Regardless, metabolic changes typically observed in
type 1 and 2 diabetic patients as characterized by hyper-
glycemia and increased circulation of free fatty acids
(FFA), are induced in both these diabetic animal models.
Consequently, in these diabetic animal models, the heart
is eventually exposed to the major compounds of a dia-
betic milieu (Dyntar et al., 2006).
In the current study, the alloxan-induced DM in rats
was confirmed by a significantly increased plasma glu-
cose concentration of 27.86 3.5 mmol/L in the diabetic
group compared with 6.06 0.2 mmol/L in the control
group when measured 24 hr after the final alloxan
injection.
A significant increase in cardiomyocyte diameter in
the right chambers of the heart and a significant
decrease in cardiomyocyte diameter in the left auricle in
test animals (P<0.05) was observed. Cardiomyocyte
diameter in the LV of test animals was not significantly
different (Table 3). Current studies report various
results in terms of changes in cardiomyocyte size in a
diabetic milieu. The results of the present study are in
accordance with the results of several researchers (Dyn-
tar et al., 2006; Grimm et al., 2002; Nunoda et al.,
Fig. 1. Rapid hyperglycemia induced changes in the rat heart. Micrograph of right atrial myocardium
from Group A (experimental diabetes group) showing (a) adiemorrhysis and (b) perifocal interstitial edema.
Haematoxylin-eosin staining. Bar5100 mm.
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1985). In contrast, other studies have reported that car-
diomyocyte size in animal experimental diabetes models
either altogether change (Kita et al., 1991), or there are
variations of only cardiomyocyte length without a
change in cardiomyocyte transverse diameter (Cagalinec
et al., 2013). Moreover, the results of the present study
directly contradict the results of other researchers (Nem-
oto et al., 2006; Stilli et al., 2007), who observed a signif-
icant decrease in cardiomyocyte transverse diameter of
cardiomyocytes of both the RV and LV of diabetic hearts.
A possible explanation for the ambiguity between the
results of previous studies and those of the present
study is a difference in the recording time of cardiomyo-
cyte length following the induction of diabetes. For
example, while Nemoto et al. (2006) reported cardiovas-
cular morphological changes 18 weeks following STZ-
induced diabetes, coinciding with systolic myocardial
dysfunction and hypertrophy of the heart ventricles,
indications of LV dysfunction have previously been
reported in rats 4–6 weeks following the induction of
experimental diabetes (Akula et al., 2003; Mihm et al.,
2001; Yu et al., 2007). These results contradict the
results of a study conducted by Stilli et al. (2007). It is
possible that the inconsistencies of reported data in
terms of cardiomyocyte length and the progression of
diabetes may be due to the employment of simple geo-
metric approximations by previous researchers, which
may inherently neglect the complexity of cardiac myo-
cyte shape and length.
The cardiomyocyte hypertrophy observed in the right
chambers of diabetic hearts in the current study
resulted in a significant increase in right atrium size
(Table 2) in the absence of changes in the size of the
heart’s left chamber. These results are in accordance
with the results of a study by Shiomi (2003) yet are in
contrast with previous studies in rats (Joffe et al., 1999;
Hoit et al., 1999).
The action of the endogenous renin-angiotensin system
(RAS) in the heart may be a further explanation for the
hypertrophy observed in the right chambers of the hearts
of experimental diabetic animals. Cardiac hypertrophy
begins as an adaptive response of the heart to
Fig. 2. Micrographs of haematoxylin-eosin stained sections of myo-
cardium. Sections from (A and C) Group B (control) and (B and D)
Group A (hyperglycemic) hearts. (A) Intact right atrial myocardium with
no signs of edema or structural changes. (B) Right atrial section exhib-
iting (a) myomalacia in the form of disappearance of banding and focal
sarcoplasm disintegration, and (b) marginal adhesion on the endothe-
lium, aggregation, and agglutination of red blood cells. (C) Section of
right ventricle with intact myocardium with no structural changes and
unaltered vascular wall. (D) Right ventricular section with marginal
adhesion on the endothelium and aggregation of red blood cells
(arrows). Bar510 mm.
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Fig. 3. Micrograph of section of Van Gieson’s st stained myocardium. Section from Group A (hypergly-
cemic) right ventricular myocardium exhibiting (a) aggregation and agglutination of red blood cells and (b)
focal destruction of the basal membranes. Bar550 mm.
Fig. 4. Micrographs of right atrial myocardial sections stained using the TTC method. (A) Group B (con-
trol) myocardium. (B) Group A (hyperglycemic) myocardium with extensive interstitial edema. Bar5 100
mm.
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hemodynamic overload or neurohumoral factors (Yama-
zaki et al., 1998). In addition, it is well recognized that
angiotensin II (Ang-II) and norepinephrine activation of
independent signaling pathways are major mechanisms
resulting in observed right chamber hypertrophy (Yama-
zaki and Yazaki, 2000). Indirect evidence supports a role
of RAS in the initiation of cell growth in smooth muscle
and myocardial cells (Katoh et al., 1989) and inhibition of
RAS has been shown to prevent LV hypertrophy in rats
with pressure overload (Kromer and Riegger, 1988; Sen,
1983) and to promote the regression of chronic pressure
overload hypertrophy in humans (Devereaux et al., 1987).
In addition, it has been reported that diabetic cardiomyop-
athy may be viewed as an Ang-II-dependent process in
which the Ang-II peptide plays a critical role in myocyte
death and hypertrophy (Fiordaliso et al., 2000).
Angiotensin-converting enzyme (ACE), a membrane-
bound enzyme, is widely distributed in cardiac vascular
endothelial cells (Balcells et al., 1997). It has previously
been shown that hypoxia has various effects on the myo-
cardium of the right and left chambers of the heart, and
that while the myocardium of the RV responds to
hypoxia with an increase of local activity and increased
expression of ACE, the myocardium of the LV responds
to hypoxia with a decrease in ACE production (Morrell
et al., 1997). Therefore, the action of endogenous ACE in
response to hemodynamic overload and hypoxia in the
early stages of diabetes may influence the development
of hypertrophy observed in the right chambers of experi-
mental diabetic hearts.
Finally, during the prolonged course of diabetes (the stage
that the majority of clinical investigations are conducted),
the rennin-angiotensin system and the endogenous chy-
mases are activated (Li et al., 2002) resulting in an increase
in general peripheral vascular resistance and blood arterial
pressure, thus causing LV hypertrophy during the chronic
stage of diabetes (Baker et al., 1992; Dedov, 2003).
In the current study, marginal adhesion of RBCs on
the endothelium with or without aggregation was
observed (Figs. 2 and 5, respectively). The results of the
present study are in accordance with the results of sev-
eral previous studies (Grigoleit et al., 1973; Yalcin et al.,
2004; Kim et al., 2006; Sun and Munn, 2006) whereby
excessive aggregation of RBCs was observed in diabetic
animals. Abnormal rheological dynamics, due to
enhanced erythrocyte aggregation, is considered the
principal cause of vascular complications in diabetes, as
red cell aggregates are unable to pass through capilla-
ries (Grigoleit et al., 1973). Moreover, hemorheological
disturbances have been reported to be present in
diabetic patients even without clinically detectable
microangiopathy (Paisey et al., 1980).
It has recently been suggested that oxidative stress,
caused by mitochondrial superoxide overproduction in
endothelial cells and hyperglycemia, are the major mecha-
nisms involved in the development of vascular complica-
tions in diabetes (Giacco and Brownlee, 2010). Oxidative
stress ultimately results in sustained activation of
antiangiogenic, proinflammatory pathways even after nor-
malization of glycemia (Giacco and Brownlee, 2010).
Hyperglycemia arises early in experimental diabetes. The
alloxan-induced rat model of diabetes, investigated in the
current study, was characterized by low systemic insulin
and marked hyperglycemia (plasma glucose level in test
animals was 27.863.5 mmol/L). Hyperglycemia results in
Fig. 5. Micrographs of myocardial sections stained using the TTC
method. (A) Group B (control) left ventricular myocardium lacking
ischemic myocytes. (B and C) Group A (hyperglycemic) right atrial
myocardium. (B) Arrows indicate intact cardiomyocytes (a) cardiomyo-
cytes with focal destruction in the form of karyolysis and karyopykno-
sis (b), and interstitial edema (c). (C) Arrows indicate ischemic
myocytes. Bar510 mm.
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activation of the enzyme, aldose reductase. This enzyme
converts excess glucose to sorbitol, which in turn is metab-
olized by sorbitol dehydrogenase to fructose (via the polyol
pathway) (Windebank and Feldman, 2001; Singleton et al.,
2003). Glucose, particularly sorbitol and fructose, reacts
nonenzymatically with proteins, lipids and nucleic acids to
produce advanced glycation end products (AGEs), which in
turn induce generation of ROS (Singh et al., 2001). Endo-
thelial ROS formation is further increased in hyperglyce-
mic environments by peroxidation of abundant glucose and
LDLs and by dysregulation of transition metals that serve
as catalysts for auto-oxidation (Cameron et al., 2001).
These mechanisms appear to be particularly important for
small arterioles, where failure of vasodilation may result
in direct tissue ischemia (Singleton et al., 2003). It is possi-
ble that the changes in the microcirculatory system
observed in the current study, such as distended vessels of
the venous collecting microcirculatory system, were a
result of the diabetic-induced hyperglycemic environment.
In accordance with these findings, it has been shown that
hyperglycemia can stimulate apoptosis of microvascular
cells through a mechanism not involving other cell types
(i.e., via activation of FOXO1) thus further contributing to
the development of the microvascular complications associ-
ated with diabetes (Behl et al., 2009).
Whether or not it is the hemorheological parameters
(hematocrit, plasma proteins, erythrocyte aggregation
and erythrocyte deformability) or the metabolic changes
(hyperglycemia, the levels of fatty acid, etc.) that are the
primary determinants of diabetes-associated microcircu-
lation abnormalities and remodeling, remains to be
determined and requires additional physiological and
epidemiological studies.
The results of the present study indicate that, in early
stage diabetes, hypertrophy and violation of myocardial
microcirculation (both aggregation and agglutination of
RBCs) occur predominantly in the right chambers of the
heart, most likely due to the specific structural charac-
teristics specific to the right chambers of the heart
(Dedov, 2003).
Fig. 6. Micrographs of haematoxylin-eosin stained sections of myocardium. Sections from (A and C)
Group B (control) and (B and D) Group A (hyperglycemic) hearts. (A) Left atrium. (B) Left atrium with (a)
intact cardiomyocytes, and (b) cardiomyocytes with focal destruction in the form of karyolysis and karyo-
pyknosis. Note marked interstitial edema. (C) Left ventricle with normal myocardium and vasculature. (D)
Left ventricle with interstitial edema. Bar510 mm.
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